Exelixis cuts 175 staffers to prioritize late-stage drug development

2024-01-08

临床1期蛋白降解靶向嵌合体临床失败财报

Exelixis is laying off 175 employees, or 13% of its workforce, to “rebalance resources” with a focus on candidates closer to market. The company appears to have cut its Phase I small molecule CDK7 inhibitor asset XL102 under investigation for solid tumors. It was not listed on the company’s Sunday pipeline update and was last referenced in its third-quarter report on Nov. 1 . The layoffs are expected to be largely completed between January and March of this year, the company said in a press release. Exelixis is expecting to incur a $25 million charge due to the restructuring. The company had 1,223 employees in December 2022, according to an SEC filing .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构